References
- Cullen M. J., Fulthorpe J. J. Stages in fiber breakdown in Duchenne muscular dystrophy: an electron-microscopic study. Journal of Neurological Science 1975; 24: 179–200
- Fukushima K., Arai M., Ogawa H., Suwa T., Satoh T. Identification of glutathione conjugate formed from loxistatin in rats. Xenobiotica 1989; 19: 521–529
- Fukushima K., Arai M., Tamai M., Yokoo C., Murata M., Suwa T., Satoh T. Metabolic fate of loxistatin in rat. Xenobiotica 1990; 20: 1043–1051
- Jasmin G., Procheck L. Hereditary polymopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X 7.1 line. Muscle and Nerve 1982; 5: 20–25
- Kar N. C., Pearson C. M. Muscular dystrophy and activation of proteinases. Muscle and Nerve 1978; 1: 308–313
- Komatsu K., Inazuki K., Hosoya J., Satoh S. Beneficial effect of new thiol protease inhibitors, epoxide derivatives, on dystrophic mice. Experimental Neurology 1986; 91: 23–29
- Stumpf W. E. Techniques for the autoradiography of diffusible compounds. Methods in Cell Biology, D. M. Prescott. Academic Press, New York 1976; vol. 13: 171–193
- Tamai M., Matsumoto K., Ohmura S., Koyama I., Ozawa Y., Hanada K. In vitro and in vivo inhibition of cysteine proteinase by EST, a new analogue of E-64. Journal of Pharmacobio-Dynamics 1986; 9: 677–677
- Tamai M., Ohmura S., Kimura M., Hanada K., Sugita H. Prolongation of life span of dystrophic hamster by cysteine proteinase inhibitor, loxistatin (EST). Journal of Pharmacobio-Dynamics 1987a; 10: 678–681
- Tamai M., Yokoo C., Murata M., Oguma K., Sota K., Sato E., Kanaoka Y. Efficient synthetic method for ethyl(+)-(2S,3S)-3-‘(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl’-2–oxiranecarboxylate (EST), a new inhibitor of cysteine proteinases. Chemical and Pharmaceutical Bulletin 1987b; 35: 1098–1104